Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Deferred Taxes: 2022-2024

Historic Deferred Taxes for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $845,000.

  • Silence Therapeutics' Deferred Taxes fell 97.96% to $1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11,000, marking a year-over-year decrease of 98.56%. This contributed to the annual value of $845,000 for FY2024, which is 11.61% down from last year.
  • As of FY2024, Silence Therapeutics' Deferred Taxes stood at $845,000, which was down 11.61% from $956,000 recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Deferred Taxes ranged from a high of $956,000 in FY2023 and a low of $688,000 during FY2022.
  • For the 3-year period, Silence Therapeutics' Deferred Taxes averaged around $829,667, with its median value being $845,000 (2024).
  • In the last 5 years, Silence Therapeutics' Deferred Taxes skyrocketed by 38.95% in 2023 and then decreased by 11.61% in 2024.
  • Over the past 3 years, Silence Therapeutics' Deferred Taxes (MRY) stood at $688,000 in 2022, then soared by 38.95% to $956,000 in 2023, then decreased by 11.61% to $845,000 in 2024.
  • Its Deferred Taxes was $845,000 in FY2024, compared to $956,000 in FY2023 and $688,000 in FY2022.